Cansino Historical Cash Flow
| 688185 Stock | 65.50 1.00 1.55% |
Analysis of Cansino Biologics cash flow over time is an excellent tool to project Cansino Biologics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 1.5 B or Begin Period Cash Flow of 2.1 B as it is a great indicator of Cansino Biologics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Cansino Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cansino Biologics is a good buy for the upcoming year.
Cansino |
About Cansino Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Cansino balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cansino's non-liquid assets can be easily converted into cash.
Cansino Biologics Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Capital Expenditures
Capital Expenditures are funds used by Cansino Biologics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cansino Biologics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Cansino Biologics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cansino Biologics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Cansino Biologics' Investments are projected to increase significantly based on the last few years of reporting. The current year's Net Borrowings is expected to grow to about 1.5 B, whereas Change To Inventory is forecasted to decline to (225.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 1.2B | 1.1B | 659.7M | 574.7M | Dividends Paid | 14.1M | 241.3M | 98.7M | 60.8M |
Cansino Biologics cash flow statement Correlations
Click cells to compare fundamentals
Cansino Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cansino Biologics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (8.1M) | (154.6M) | (706.4M) | (604.0M) | (214.4M) | (225.1M) | |
| Investments | (709.9M) | (60.1M) | (1.4B) | (259.8M) | 519.9M | 545.8M | |
| Change In Cash | 144.6M | 4.2B | 1.0B | (2.1B) | (774.6M) | (735.9M) | |
| Net Borrowings | (7.3M) | (22.5M) | 969.1M | 1.2B | 1.4B | 1.5B | |
| Free Cash Flow | (287.1M) | (740.2M) | 811.4M | (3.0B) | (1.9B) | (1.8B) | |
| Change In Working Capital | (12.8M) | (100.8M) | 84.3M | (1.5B) | (157.0M) | (164.8M) | |
| Begin Period Cash Flow | 57.4M | 202.0M | 4.4B | 5.5B | 3.0B | 2.1B | |
| Total Cashflows From Investing Activities | (813.7M) | (319.7M) | (2.6B) | (1.2B) | (1.1B) | (1.2B) | |
| Other Cashflows From Financing Activities | (20.9M) | (13.6M) | 598.6M | (368K) | (423.2K) | (402.0K) | |
| Depreciation | 18.5M | 24.6M | 73.4M | 178.2M | 269.1M | 282.5M | |
| Other Non Cash Items | (44.5M) | (3.1M) | (31.6M) | (199.5M) | (75.8M) | (79.6M) | |
| Capital Expenditures | 116.9M | 288.3M | 1.2B | 1.1B | 659.7M | 574.7M | |
| Total Cash From Operating Activities | (154.2M) | (349.9M) | 2.0B | (1.9B) | (916.3M) | (870.4M) | |
| Change To Account Receivables | (8.6M) | (107.8M) | (419.9M) | (495.8M) | (446.2M) | (423.9M) | |
| Net Income | (156.8M) | (396.6M) | 1.9B | (909.4M) | (1.4B) | (1.4B) | |
| Total Cash From Financing Activities | 1.1B | 4.9B | 1.6B | 854.2M | 982.4M | 1.6B | |
| End Period Cash Flow | 202.0M | 4.4B | 5.5B | 3.4B | 2.3B | 2.5B | |
| Other Cashflows From Investing Activities | 13.2M | 28.7M | 45.8M | 107.2M | 123.2M | 129.4M | |
| Change To Netincome | (43.7M) | 5.4M | (66.6M) | 821.2M | 944.4M | 991.7M | |
| Change To Liabilities | (2.5M) | 269.7M | 1.2B | (859.9M) | (773.9M) | (735.2M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Cansino Stock
The Cash Flow Statement is a financial statement that shows how changes in Cansino balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cansino's non-liquid assets can be easily converted into cash.